plerixafor (Mozobil)
Jump to navigation
Jump to search
Indications
- used prior to stem cell transplantation
- investigational for treatment of NSCLC[2][3]
Mechanism of action
- hematopoietic stem cell mobilizer
- maximizes stem cell collection
- CXCR4 antagonist[2][3]
Notes
Manufacturer: Genzyme
More general terms
Additional terms
References
- ↑ Prescriber's Letter 16(2): 2009 New Drugs Approved by the FDA in 2008 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250213&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 2.2 Burger JA, Stewart DJ. CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opin Investig Drugs. 2009 Apr;18(4):481-90. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19335276
- ↑ 3.0 3.1 3.2 Burger JA, Stewart DJ, Wald O, Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther. 2011 Apr;11(4):621-30. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21504328